Eton Pharmaceuticals Retains Commercial Rights to ET-900
Eton Pharmaceuticals retains commercial rights to ET-900 for pediatric neurology.
Related stories
Grifols reports Q3 group profit of €162 million
M impact | EQUITY | Nov 02, 2026, 04:43 PM UTC
Coface New Business Hits Record €105M for 9M-26
Coface said new business reached a record €105 million for 9M-26.
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Q·CAPITAL Q3 Comprehensive Loss Widens to CHF 842,361
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Q·CAPITAL’s Q3 2026 Loss Widens
Q·CAPITAL reported a wider loss in the third quarter of 2026 than a year earlier.
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Coface Reports Net Income, Including Third-Quarter Results
Coface reported an annualized RoATE.
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC
Grifols Reports Q3 Revenue of €538 Million
M impact | EQUITY | Nov 02, 2026, 04:37 PM UTC